Nomir Medical to Present Positive In Vivo Data on MRSA Resistance ...

Tag : resistance
Nomir Medical Technologies, a leader in the development of opticalenergy technologies for anti-infective medical applications,announced today that the Company will present an abstract detailingpositive in vivo human data from its study of Methicillin-resistantS. aureus (MRSA) resistance reversal and eradication in the nares(nose) using Noveon(R), a novel dual-wavelength optical energydevice. Noveon is designed to effect near-infrared photo-damage andphoto-inactivation of bacteria and fungi at energies andtemperatures that are safe to normal and healthy tissue.

The detailed data will be presented at the Termis North AmericaAnnual Conference and Exhibition in San Diego, December 7-10, 2008.

Nomir has completed two IRB-approved human studies with Noveonagainst MRSA carriage and infection in the human nares. Based ondata from these studies, Nomir plans to initiate a proof-of-conceptstudy for Noveon for the reduction of bioburden in diabetic footulcers. Additionally, in May 2008, the Company initiated a pivotalproduct registration trial for Noveon for the treatment ofonychomycosis.

About Nomir

Nomir Medical Technologies, Inc. is a medical device company with aproduct pipeline of optical energy therapeutics being developed formultiple clinical applications. Nomir's light-based systems targetthe elimination of bacterial and fungal infections, while alsopromoting healthy tissue recovery. This potential therapy-alteringtechnology may enhance the effectiveness of, or even reduce theneed for antibiotics and antifungal agents, and may be associatedwith fewer treatment side-effects. Nomir has a broad patentportfolio with pending systems, methods and unique photobiologicalmechanism claims for near infrared photodamage to bacterial andfungal pathogens. www.nomirmedical.com

Forward-looking statements

Certain statements contained in this press release containing wordslike believe, intend, may, expect, project and other similarexpressions are forward-looking statements involving a number ofrisks and uncertainties. Factors that can cause actual results todiffer materially from those projected in the Company'sforward-looking statements include the following: market acceptanceof our technologies, therapies, and products; our ability to obtainfinancing; our financial and technical resources relative to thoseof our competitors; our ability to keep up with rapidly changingtechnologies; government regulations of our technologies; ourability to assert and enforce our intellectual property rights andprotect our proprietary technologies; the ability to attract andretain key employees; the ability to obtain and develop partnershipopportunities; the timing of commercial product launches; theability to achieve key milestones in key products and other risksfactors from time to time in the Company's announcements.